
Step closer for Stargardt treatment
Ocugen announced the US Food and Drug Administration (FDA) has granted rare paediatric disease designation for OCU410ST, the company’s gene therapy for ABCA4-associated retinopathies including Stargar

Ocugen announced the US Food and Drug Administration (FDA) has granted rare paediatric disease designation for OCU410ST, the company’s gene therapy for ABCA4-associated retinopathies including Stargar

The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to new research by the University of Auckland. Led by Dr Natalia Bove

The team behind the Vision Bus Aotearoa (VBA) is seeking new funding to support continued mobile eyecare service delivery to underserved schools, primarily in the South Auckland region. Funded entir

Driven by passion and creative freedom, Marseille-based JF Rey has grown to international recognition during the past four decades. “Today, this anniversary not only allows us to celebrate the path we’ve followed, but also to reaffirm our bold, ever-evolving vision for the future,” the company said.

An international study found metastasis occurred in 10% of conjunctival melanoma patients, with the liver and lungs the most commonly reported sites (45% each). A total of 288 patients with conjunct

Taking pride of place on Ophthalmic Instrument Company’s (OIC’s) stand at RANZCO NZ was the new Reticam 3100 Plus, an ultra-widefield (UWF) retinal camera from SysEye.

GNZ is launching Sightwise, a programme to educate and support glaucoma patients, improve outcomes and reduce the burden on eye departments

A new European licensing agreement provides overseas boost for The Auckland Optotypes

Special Olympics Lions Club International Opening Eyes (SOLCIOE) is seeking passionate optometrists, dispensing opticians and optical assistants to volunteer for the Special Olympics Opening Eyes Visi

Pharmac has swapped funding from nepafenac (Ilvero) to diclofenac sodium (Devatis) eye drops. Ilevro nepafenac drops were a temporary replacement for Voltaren Ophtha, for which there were supply gaps

Eye Institute (EI) is partnering with Eye Specialists in Whangarei, delivering on its long-term commitment to serve the New Zealand public in the regions as well as in the centres.

The prevalence of childhood blindness in Aotearoa has fallen from 0.05% in 2012 to 0.01% in 2024 and low vision from 0.06% to 0.03%, according to a new study led by Dr Cheefoong Chong.